320 related articles for article (PubMed ID: 11713814)
1. DNA-based immunisation against rabies and rabies-related viruses: towards multivalent vaccines.
Perrin P; Jacob Y; Desmézières E; Tordo N
Dev Biol (Basel); 2000; 104():151-7. PubMed ID: 11713814
[TBL] [Abstract][Full Text] [Related]
2. Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines.
Desmézières E; Jacob Y; Saron MF; Delpeyroux F; Tordo N; Perrin P
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2343-2351. PubMed ID: 10501486
[TBL] [Abstract][Full Text] [Related]
3. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC
J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155
[TBL] [Abstract][Full Text] [Related]
4. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
[TBL] [Abstract][Full Text] [Related]
5. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice.
Kaur M; Saxena A; Rai A; Bhatnagar R
FASEB J; 2010 Jan; 24(1):173-83. PubMed ID: 19741168
[TBL] [Abstract][Full Text] [Related]
6. Rabies: epidemiological tendencies and control tools.
Tordo N; Bahloul C; Jacob Y; Jallet C; Perrin P; Badrane H
Dev Biol (Basel); 2006; 125():3-13. PubMed ID: 16878455
[TBL] [Abstract][Full Text] [Related]
7. Development of combined vaccines for rabies and immunocontraception.
Wu X; Franka R; Svoboda P; Pohl J; Rupprecht CE
Vaccine; 2009 Nov; 27(51):7202-9. PubMed ID: 19925954
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.
Xiang ZQ; Spitalnik S; Tran M; Wunner WH; Cheng J; Ertl HC
Virology; 1994 Feb; 199(1):132-40. PubMed ID: 8116236
[TBL] [Abstract][Full Text] [Related]
9. Rabies DNA vaccination by the intranasal route in dogs.
Tesoro Cruz E; Hernández González R; Alonso Morales R; Aguilar-Setién A
Dev Biol (Basel); 2006; 125():221-31. PubMed ID: 16878480
[TBL] [Abstract][Full Text] [Related]
10. Canine adenovirus based rabies vaccines.
Tordo N; Foumier A; Jallet C; Szelechowski M; Klonjkowski B; Eloit M
Dev Biol (Basel); 2008; 131():467-76. PubMed ID: 18634509
[TBL] [Abstract][Full Text] [Related]
11. Development of rabies DNA vaccine using a recombinant plasmid.
Rai N; Kaushik P; Rai A
Acta Virol; 2005; 49(3):207-10. PubMed ID: 16178518
[TBL] [Abstract][Full Text] [Related]
12. A DNA vaccine that encodes rabies virus glycoprotein lacking transmembrane domain enhances antibody response but not protection.
Gupta PK; Sharma S; Walunj SS; Patil AA; Rai A; Saini M
Acta Virol; 2006; 50(2):87-92. PubMed ID: 16808325
[TBL] [Abstract][Full Text] [Related]
13. Production, purification and analysis of an experimental DNA vaccine against rabies.
Diogo MM; Ribeiro SC; Queiroz JA; Monteiro GA; Tordo N; Perrin P; Prazeres DM
J Gene Med; 2001; 3(6):577-84. PubMed ID: 11778904
[TBL] [Abstract][Full Text] [Related]
14. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.
Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC
Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715
[TBL] [Abstract][Full Text] [Related]
15. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.
Xiang ZQ; Yang Y; Wilson JM; Ertl HC
Virology; 1996 May; 219(1):220-7. PubMed ID: 8623532
[TBL] [Abstract][Full Text] [Related]
16. A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals.
Niederhäuser S; Bruegger D; Zahno ML; Vogt HR; Peterhans E; Zanoni R; Bertoni G
Vaccine; 2008 Dec; 26(52):6749-53. PubMed ID: 18955098
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses.
Borrego B; Fernandez-Pacheco P; Ganges L; Domenech N; Fernandez-Borges N; Sobrino F; Rodríguez F
Vaccine; 2006 May; 24(18):3889-99. PubMed ID: 16563575
[TBL] [Abstract][Full Text] [Related]
18. Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals.
Lodmell DL; Esposito JJ; Ewalt LC
Vaccine; 2004 Sep; 22(25-26):3329-33. PubMed ID: 15308356
[TBL] [Abstract][Full Text] [Related]
19. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.
Li J; Faber M; Papaneri A; Faber ML; McGettigan JP; Schnell MJ; Dietzschold B
Virology; 2006 Dec 5-20; 356(1-2):147-54. PubMed ID: 16938327
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to nucleic acid vaccines to rabies virus.
Xiang ZQ; Spitalnik SL; Cheng J; Erikson J; Wojczyk B; Ertl HC
Virology; 1995 Jun; 209(2):569-79. PubMed ID: 7778289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
